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Background: Most colorectal cancers (CRC) arise sporadically from precursor lesions: 26 
colonic polyps. Polyp resection prevents progression to CRC. Risk of future polyps is 27 
proportional to the number and size of polyps detected at screening, allowing identification of 28 
high-risk individuals who may benefit from effective chemoprophylaxis. We aimed to 29 
investigate the potential of 5-aminosalicylic acid (5-ASA), a medication used in the treatment 30 
of ulcerative colitis, as a possible preventative agent for sporadic colorectal cancer. 31 
Methods: Human colorectal adenoma (PC/AA/C1, S/AN/C1 and S/RG/C2), transformed-32 
adenoma PC/AA/C1/SB10 and carcinoma cell lines (LS174T and SW620) were treated with 33 
5-ASA. The effect on growth in 2- and 3-dimensional (2D, 3D) culture, β-catenin 34 
transcriptional activity and on cancer stemness properties of the cells were investigated. 35 
Results: 5-ASA was shown, in vitro, to inhibit growth of adenoma cells and suppress β-36 
catenin transcriptional activity. Downregulation of β-catenin was found to repress expression 37 
of stem cell marker LGR5 and functionally suppress stemness in human adenoma and 38 
carcinoma cells using 3D models of tumorigenesis.  39 
Conclusions: 5-ASA can suppress the cancer stem phenotype in adenoma-derived cells. 40 
Affordable and well-tolerated, 5-ASA is an outstanding candidate as a chemoprophylactic 41 
medication to reduce the risk of colorectal polyps and CRC in those at high risk.  42 
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Colorectal cancer (CRC) is one of the most common malignancies worldwide and, despite 47 
advances in treatment, is the second-most common cause for cancer-related mortality1. Of 48 
concern, the incidence of CRC appears to be rising in adults under the age of 502,3. CRC 49 
derives from pre-neoplastic precursor lesions – polyps – which can be resected before 50 
malignant transformation. Accordingly, many countries have employed national screening 51 
programmes which allow identification of polyps and cancers at early stages when they are 52 
more amenable to curative treatment. These screening programmes also allow identification 53 
of individuals at high risk of CRC: in the recent joint British Society of 54 
Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health 55 
England guidelines, individuals with high-risk findings are offered further surveillance 56 
colonoscopy (high risk findings are defined by the presence of either (a) two or more polyps 57 
(excluding diminutive hyperplastic rectal polyps 1 – 5mm) of which one polyp is ≥ 10mm or 58 
(b) ≥5 polyps of any size)4. Despite this, there is currently no chemoprophylaxis that is 59 
offered to reduce the risk of further polyps or CRC for these individuals. 60 
Aspirin has demonstrated promise as a chemoprophylactic drug in this context; several 61 
clinical trials have reported a reduction in adenoma number with regular aspirin use5,6. Most 62 
recently, the seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention 63 
trial recruited patients with high-risk endoscopic findings from the English Bowel Cancer 64 
Screening Programme and reported reduced number of polyps in the aspirin treated group 65 
at follow-up colonoscopy (although the adenoma detection rate was not significantly 66 
reduced)7. Further, clinical trials have demonstrated reduced colorectal polyp burden in 67 
patients with the hereditary cancer syndrome Familial Adenomatous Polyposis and halved 68 
the incidence of CRC in patients with Lynch syndrome following aspirin use8. This has 69 
resulted in the recent recommendation by the National Institute of Clinical Excellence (NICE) 70 
endorsing the prescription of prophylactic aspirin for Lynch syndrome mutation carriers9. 71 




of two recent, large randomised controlled trials10,11. The ARRIVE (Aspirin to Reduce Risk of 73 
Initial Vascular Events) trial reported that 100mg aspirin daily doubled the risk of 74 
gastrointestinal bleeding (hazard ratio 2.11, 95% confidence interval (CI) 1.36 – 3.28)10, 75 
similar to that reported in the ASPREE trial (HR 1.87, 95% CI 1.32 – 2.66)11. The ASPREE 76 
(Aspirin in Reducing Events in the Elderly) trial also reported that the risk of intracranial 77 
bleeding was increased by 50% in healthy adults over 70 years old (HR 1.5, 95% CI 1.11 – 78 
2.02)11. Consequently, aspirin may not be a suitable chemoprophylactic drug in all patients 79 
and certainly the benefit and harm needs to be carefully assessed before use12.  80 
5-aminosalicylic acid (5-ASA) is a non-steroidal anti-inflammatory drug structurally similar to 81 
aspirin which is commonly prescribed to induce and maintain remission in chronic idiopathic 82 
inflammatory bowel disease (IBD). Conventional subclassification of inflammatory bowel 83 
disease distinguishes two phenotypically categorized conditions: Ulcerative Colitis (UC) and 84 
Crohn’s Disease (CD). UC and CD are both associated with an increased risk of CRC: so-85 
called colitis associated cancer (CAC)13,14.  86 
Although a complete understanding of the anti-inflammatory mechanisms of 5-ASA is 87 
lacking, existing data implies that 5-ASA has efficacy in suppressing multiple pro-88 
inflammatory pathways: 5-ASA has been demonstrated to antagonise several pro-89 
inflammatory mediators including interferon-gamma (IFNγ)15, tumour necrosis factor α 90 
(TNFα)15,16 and nuclear factor kappa B (NFκB)16,17, which may be, at least in part, due to 91 
agonism of peroxisome proliferator-activated receptor gamma (PPARγ)18. Information from 92 
epidemiology studies is limited, but early observational data indicated that 5-ASA reduced 93 
the risk of CAC19 although a 2012 meta-analysis reported a protective effect in clinic-based 94 
studies with no effect in population-based studies20. However, the two most-recent meta-95 
analyses by Qiu et al21 and Bonovas et al22 reported dose-dependent protective effects of 96 
oral mesalazine across a range of study designs, including pooled analysed of population-97 
based studies, in ulcerative colitis. Accordingly, the European Crohn’s and Colitis 98 




Importantly, 5-ASA is well-tolerated, is not associated with increased risk of bleeding, and is 100 
affordable for health providers. However, it remains unknown whether 5-ASA confers a 101 
reduced risk of developing sporadic CRC. 102 
The mechanisms underpinning the apparent antineoplastic activity of 5-ASA in CAC have 103 
not been fully elucidated but existing data from models of CRC have suggested that 5-ASA 104 
may suppress Wnt/β-catenin through multiple mechanisms including those implicated in its 105 
anti-inflammatory role including induction of PPARγ18,24; suppression of the cyclo-106 
oxygenase-2 (COX-2)/prostaglandin E2 (PGE2) axis25; post-translational modification of the 107 
β-catenin phosphatase protein phosphatase 2A (PP2A)26. 5-ASA may also promote 108 
membranous sequestration of β-catenin through N-glycosylation of and membranous 109 
translocation of E-cadherin27; negative regulation of the serine/threonine protein kinase 110 
PAK128; upregulation of µ-protocadherin29. Importantly, mutations resulting in upregulated 111 
Wnt/β-catenin signalling are among the first observed in colorectal adenomas and have 112 
been demonstrated as being sufficient for early adenoma formation30. Evidence that 5-ASA 113 
inhibits the β-catenin signalling in adenomas comes from immunohistochemical analysis as 114 
part of the German 5-ASA Polyp Prevention Trial: Munding and colleagues reported reduced 115 
expression of β-catenin in adenomas from patients taking 1g 5-ASA/day31. However, to date, 116 
these results have not been validated either in vitro or in vivo in human adenoma, and the 117 
effect of 5-ASA on adenoma growth is unknown. Further, given that Wnt/β-catenin signalling 118 
is important for the maintenance of the colonic stem compartment32, we hypothesised that 119 
suppression of dysregulated Wnt/β-catenin may suppress the stem phenotype which, 120 
crucially, may prevent adenoma formation and progression in sporadic disease.  121 
Whilst the effect of 5-ASA on the growth of carcinoma-derived cells in vitro has been 122 
described33-38, no such data exists for cells derived from colonic adenomas. In this study we 123 
aimed to establish the effect of 5-ASA on Wnt/β-catenin and stem cell phenotype in human 124 




understand whether 5-ASA may be an effective chemoprophylactic drug for individuals at 126 
high risk of sporadic CRC.  127 





Cell lines & culture: The colorectal adenoma-derived cell lines PC/AA/C1, S/AN/C1, 130 
S/RG/C2 and the transformed adenoma derived cell line PC/AA/C1/SB10 used in these 131 
experiments were established in this laboratory, their derivation and characterisation have 132 
been  previously described39-41.  Growth medium was Dulbecco’s Modified Eagle Medium 133 
(DMEM) (Gibco; Thermo Fisher Scientific, MA, USA) supplemented with 20% foetal bovine 134 
serum (FBS), 1µg/ml hydrocortisone sodium succinate (Sigma-Aldrich; Merck, MO, USA), 135 
0.2 units/ml insulin (Sigma-Aldrich; Merck, MO, USA), 2 mM glutamine (Gibco; Thermo 136 
Fisher Scientific, MA, USA), 100 units/mL penicillin and 100 μg/mL streptomycin (Gibco; 137 
Thermo Fisher Scientific, MA, USA). The CRC-derived cell lines LS174T and SW620 were 138 
obtained from American Type Culture Collection (ATCC; Rockville, MD, USA) were cultured 139 
in DMEM supplemented with 10% FBS, 2mM glutamine, 100units/mL penicillin and 100 140 
units/mL streptomycin.  All cell lines were routinely assessed for microbial contamination 141 
(including mycoplasma) and characterised using an inhouse panel of cellular and molecular 142 
markers to check that cell lines have not been cross contaminated (every 3-6 months; data 143 
not shown). Stocks were securely catalogued and stored, and passage numbers strictly 144 
adhered to prevent phenotypic drift. 145 
Treatments: 5-aminosalicylic acid (Sigma-Aldrich; Merck, MO, USA), was dissolved in 146 
culture media, pH-balanced to 7.35 – 7.45, sterile-filtered and supplemented with HEPES 147 
buffer solution 1M (Sigma-Aldrich; Merck, MO, USA)(20µL per 1mL 5-ASA solution). 148 
All cell lines were seeded into 25cm2 tissue culture flasks (T25; Corning, NY, USA): all 149 
adenoma-derived cell lines were seeded at 2 x 106 cells/flask (except PC/AA/C1, seeded at 150 
4 x 106 cells/flask), transformed adenoma and CRC-derived cell lines at 1 x 106 cells/flask. 151 
Seeding densities were calculated so that all cell lines were 70% confluent when treated with 152 
5-ASA. After 72 hours the culture media was replaced by 20-40mM 5-ASA/culture media 153 
solution. At 24, 48 and 72 hours after addition of 5-ASA, attached cells were trypsinised and 154 




Immunoblotting: Whole cell lysates were prepared in situ, on ice and analysed by western 156 
blotting as previously described42 using antibodies to the following: AXIN-2 (2151, Cell 157 
Signaling, MA, USA, 1:1000), β-catenin (9587, Cell Signaling, MA, USA, 1:5000), active-β-158 
catenin (05-665, Millipore, Sigma, MA, USA, 1:1000), c-MYC (SC-40, Santa Cruz 159 
Biotechnology, CA, USA, 1:200), LEF-1 (2230, Cell Signaling, MA, USA, 1:1000) & LGR5 160 
(Ab75850, Abcam, Cambridge, UK, 1:1000). Equal loading was confirm using β-actin 161 
(A5316, Sigma-Aldrich, Merck, MO, USA. 1:1000) or α-tubulin (T9026, Sigma-Aldrich, 162 
Merck, MO, USA. 1:10000). 163 
TOPflash reporter assay: Cells were treated with 5-ASA 24 hours after transfection with 164 
TOPflash/FOPflash and SV40-Renilla plasmids as previously described43 using the Promega 165 
Dual Luciferase Reporter Assay System (Promega, WI, USA) according to the 166 
manufacturer’s instructions. FOPflash reporter with mutated TCF consensus sites was used 167 
to control for non-specific output. Luminescence was measured at 560nm using a Modulus 168 
luminometer (Turner Biosciences, CA, USA).  169 
RNA interference: Cells were transfected using Lipofectamine RNAiMAX (Invitrogen, 170 
Thermo Fisher Scientific, MA, USA), according to the manufacturer's protocol, with small 171 
interfering RNAs (siRNAs, final concentration 50 nM; Dharmacon, Horizon Discovery, 172 
Cambridge, UK) targeting LEF-1, or a negative control, for which four different siRNA 173 
sequences were pooled44. Cells were incubated overnight at 37˚C before medium changing. 174 
Samples were prepared 72 hours after transfection. 175 
Spheroid formation assay: Spheroids formed from adenoma and carcinoma-derived cells 176 
were grown using an adapted protocol from the original Sato paper45. Cells were 177 
resuspended in Matrigel (Corning, NY, USA) as a single-cell suspension and seeded into 24-178 
well plates (Corning, NY, USA) as described previously46. The Matrigel hemispheres were 179 
allowed to polymerise before being submerged in advanced DMEM:F12 (Gibco, Thermo 180 
Fisher Scientific, MA, USA) supplemented with 0.1% bovine serum albumin (Sigma-Aldrich, 181 




HEPES (Sigma-Aldrich, Merck, MO, USA), 100units/mL penicillin and 100units/mL 183 
streptomycin (Gibco; Thermo Fisher Scientific, MA, USA), 1% N2 (Thermo-Fisher Scientific, 184 
MA, USA), 2% B27 (Thermo-Fisher Scientific, MA, USA) and 0.2% N-acetylcysteine (Sigma-185 
Aldrich, Merck, MO, USA). For spheroid culture of PC/AA/C1 adenoma-derived cells, 186 
spheroid medium was further supplemented with hEGF (Peprotech, London, UK), 50ng/mL. 187 
The culture media was refreshed twice weekly over the course of 21 days in culture. Wells 188 
were imaged as Z-stacks using a Leica DM16000 widefield microscope and LAS-X software 189 
(both Leica Microsystems, Wetzlar, Germany) on days 7, 11, 14, 18 and 21. Images 190 
acquired were analysed using MATLAB R2015a software (MathWorks, MA, USA). 191 
Quantitative‑PCR (qPCR): Total RNA was extracted from spheroids using TRI-reagent 192 
(Sigma-Aldrich, Merck, MO, USA), a RNeasy mini kit (Qiagen, Hilden, Germany) was utilised 193 
according to the manufacturer's protocol with an additional on-column DNase digestion step 194 
(RNase-Free DNase Set; Qiagen, Hilden, Germany). Complementary (c) DNA synthesis was 195 
synthesised from 2 µg RNA, using the RNA-dependent DNA polymerase, Moloney murine 196 
leukaemia virus reverse transcriptase, (Promega WI, USA). The samples were diluted to a 197 
final concentration of 10 ng/µl. Following optimisation of primers and ensuring the annealing 198 
temperature provided ~100% amplification efficiency per cycle (data not shown), qPCR was 199 
performed, as previously described47, using SYBR Green PCR mix (Qiagen, Hilden, 200 
Germany) and the following Qiagen QuantiTect primers, LGR5 (cat. no. QT00027720) and 201 
CD133 (cat. no. QT00075586), with gene expression normalised interchangeably with both 202 
housekeeping genes TATA-binding protein (TBP; cat. no. QT00000721) or Hypoxanthine 203 
Phosphoribosyl Transferase (HPRT; cat. no. QT00059066). Amplification data was analysed 204 
using MxPro software version 4.10 (Agilent Technologies, CA, USA). 205 
Statistical analysis: All statistical analysis was performed using GraphPad Prism software, 206 
student edition (GraphPad Software, California, USA). P values were determined using 207 
either one sample t-test or one-way ANOVA testing with Bonferroni post-test. Results are 208 





5-ASA suppresses the growth of adenoma- and CRC-derived cells in vitro 211 
Three adenoma-derived cell lines (PC/AA/C1, S/AN/C1 and S/RG/C2) were seeded in T25 212 
flasks for 72 hours before treatment with 20mM or 40mM 5-ASA (consistent with 213 
concentrations used previously33-38) and the attached cell yield and floating cells counted 214 
after 24, 48 and 72 hours (Figure 1A). This experiment was also carried out in the 215 
transformed adenoma cell line PC/AA/C1/SB10 and two CRC cell lines (LS174T and 216 
SW620, Figure 1A). 5-ASA inhibited the number of attached cells in all adenoma derived cell 217 
lines treated with either 20mM or 40mM 5-ASA. Of interest, the adenoma-derived cell lines 218 
were as sensitive to 5-ASA treatment as the tumorigenic cell lines (Figure 1A).  219 
In 2 of the 3 adenoma derived cell lines, there was a significant induction of floating cells 72 220 
hours after 40mM 5-ASA treatment, indicative of cell death. However, the reduction in cell 221 
yield on treatment with 5-ASA could not be explained by induction of cell death alone; in 222 
support of this, blocking apoptosis with the pan caspase inhibitor (Q-VD-OPh) did not rescue 223 
the reduction in cell yield on 40mM 5-ASA treatment (Figure 1B). Furthermore, although 5-224 
ASA induced apoptosis in cancer derived cells LS174T, blocking it also had no effect the 225 
inhibition of cell yield when treated with 40mM 5-ASA (Supplementary Figure 1A); this is 226 
consistent with 5-ASA inducing growth inhibition in the cancer cells as previously reported33-227 
38.  Taken together, these results show that 5-ASA causes growth inhibition in both the 228 
colorectal adenoma and carcinoma derived cells. 229 
 230 
5-ASA downregulates Wnt/β-catenin signalling in human adenoma and carcinoma 231 
cells 232 
To measure the effect of 5-ASA on β-catenin/TCF-mediated transcription activity in 233 
adenoma derived cells, we treated PC/AA/C1 (APC mutant) adenoma-derived cells with 5-234 




LS174T (β-catenin mutant) carcinoma-derived cells. These cell lines were chosen as 236 
representative of tumours with disrupted β-catenin signalling, important for the initiation of 237 
colorectal carcinogenesis. At 24 hours treatment 40mM 5-ASA TOPflash activity was 238 
significantly suppressed (Figure 2A and B, results for the transformed adenoma derived cells 239 
are shown in supplementary Figure 1B). A similar, but not statistically significant trend was 240 
observed for cells treated with 20mM 5-ASA. Interestingly, total cellular β-catenin levels and 241 
active dephosphorylated β-catenin were unchanged on western blots after 5-ASA treatment 242 
in all cell lines (Figure 2C and supplementary figures 2A and C). Next, we investigated β-243 
catenin target expression after treatment with 5-ASA (Figure 2E and Supplementary Figure 244 
2B and D). Accordingly, known β-catenin-regulated proteins AXIN-2, c-MYC and LEF-1 were 245 
downregulated by 20mM and 40mM 5-ASA in both a dose- and time-dependent manner with 246 
the most marked effects observed at the higher dose at the 72 hour time point (Figure 2E 247 
and Supplementary Figure 2B and D).  248 
 249 
5-ASA reversibly suppresses expression of the stem-marker LGR5 in colorectal 250 
adenoma and carcinoma cells  251 
Leucine rich G-protein coupled receptor-5 (LGR5) is an established marker of crypt-base 252 
stem cells48. LGR5 expression is frequently expressed in adenoma and tumour metastases 253 
but expression in primary CRC is variable49 (Figure 3A). Western blots show that 5-ASA 254 
suppresses expression of LGR5 in 2/3 adenomas, the transformed adenoma and both CRC-255 
derived cells, over a 72 hour period (Figure 3B). Because LGR5 is a β-catenin-regulated 256 
gene, we hypothesised that the effect of 5-ASA would be reversible, important for 257 
maintenance of tissue homeostasis in the surrounding colonic epithelium. To determine 258 
whether expression of LGR5 recovered on removal of 5-ASA, PC/AA/C1 adenoma cells 259 
were treated with 5-ASA for 72 hours before washing the cells and culturing for a further 3 260 




within 12 hours of stopping 5-ASA treatment in PC/AA/C1 cells (Figure 3C) with expression 262 
returning to baseline 48 hours after stopping treatment.    263 
 264 
Low-dose 5-ASA reduces the ability of PC/AA/C1 cells to form spheroids 265 
LGR5+ stem cells form spheroid structures when grown in extra-cellular matrix gels such as 266 
Matrigel, complete with differentiated colonic cells and hierarchical organisation as seen in 267 
the gastrointestinal tract in vivo45. As such, the ability of cells to form spheroids from single 268 
cell suspensions is considered an assay of stemness50.  269 
 270 
To establish whether 5-ASA could inhibit stem cell function, PC/AA/C1 cells were seeded as 271 
a single cell suspension into Matrigel.  As PC/AA/C1 cells were more sensitive to 5-ASA in 272 
3D culture than 2D culture, they were treated with 1-5mM 5-ASA at the time of seeding. 273 
5mM 5-ASA treatment was sufficient to significantly block spheroid formation as well as 274 
growth of the adenoma derived cells (Figure 4); there were significantly fewer spheroids after 275 
7 days in 3D culture (Figure 4A). Additionally, spheroid size analysis showed 5-ASA 276 
treatment resulted in significantly smaller spheroids after 21 days in culture (Figure 4B-E). 277 
Similar findings were noted for LS174T-derived CRC spheroids (Figure 4F-I). Furthermore, 278 
the mRNA expression of stem cell associated proteins LGR5 and CD133 was significantly 279 
decreased in the 2mM and 5mM treated PC/AA/C1 and LS174T cells (Figure 4J-K).  280 
 281 
Importantly, when these experiments were repeated with 5-ASA removed from the culture 282 
media at day 7, the growth inhibitory effect on the PC/AA/C1 spheroids was sustained for a 283 
further 14 days in culture (Figure 5A-D). Similar results were obtained for LS174T CRC-284 




stem cell potential of the cells, as both the number and the growth of the spheroids was 286 
unable to fully recover to that of the untreated spheroids once the 5-ASA is removed.  287 
 288 
Discussion 289 
The results presented here provide new insights into the effect of 5-ASA, an affordable and 290 
well-tolerated drug, on the growth and stemness-potential of adenoma-derived cells in vitro. 291 
Important for use in a cancer prevention setting, this is the first report to document the effect 292 
of 5-ASA on adenoma-derived spheroids in 3D culture. 3D cell culture using spheroids is a 293 
useful model for studying stem function; this is exemplified by elegant work from the Sato 294 
group who generated a ‘library’ of spheroids derived from colorectal adenoma and 295 
carcinomas and demonstrated that not only did niche-dependency decrease along the 296 
adenoma-carcinoma sequence, but that spheroids reproduced the histopathological grade 297 
and differentiation capacity of their parental tumours both in vitro and as xenografts51. Our 298 
data demonstrated that 5-ASA consistently negatively regulated Wnt/β-catenin activity and 299 
target gene expression, directly antagonising a key signalling pathway of the colonic stem 300 
compartment. Further, for the first time 5-ASA was demonstrated to negatively regulate 301 
expression of the stem cell marker LGR5 (and stem associated protein CD133). In addition, 302 
by blocking the formation of adenoma-derived spheroids, 5-ASA was shown to functionally 303 
suppress stemness.  304 
 305 
Targeting adenoma cells with stem-cell properties is important because colorectal 306 
tumorigenesis is believed to be initiated and driven by a subpopulation of cells with 307 
properties of stemness – cancer stem cells – typified by asymmetric cell division and slow 308 
cell turnover making them resistant to traditional chemotherapeutics52. Lineage-tracing 309 
experiments have demonstrated that LGR5+ cells act as stem cells in mouse adenoma and 310 




have demonstrated that these cells have the ability to generate both differentiated cells and 312 
self-renew53. Further, LGR5+ cells drive adenoma growth in mouse models54 and promote 313 
adenoma cell survival in human adenoma49. Baker and colleagues48 demonstrated using in-314 
situ hybridization that LGR5 expression is increased in adenomas with expression 315 
throughout the adenomatous gland, with a heterogenous distribution and loss of stem 316 
hierarchy observed in normal mucosa. Because LGR5 is a ‘Wnt amplifier’55,56 expansion of 317 
LGR5+ cells may be a key step in allowing cells without permissive mutations in other pro-318 
oncogenic signalling pathways to expand, driving formation of adenomas. Thus, it is possible 319 
that suppression of LGR5 may suppress the stem potential of adenoma cells and may 320 
prevent adenoma formation. Importantly, suppression of β-catenin transcriptional activity and 321 
spheroid formation was demonstrated at 5-ASA concentrations that are achievable with 322 
available 5-ASA preparations: oral 5-ASA preparations equivalent to 2g/day achieve luminal 323 
concentrations of 12 – 22.7mM57. This corresponds with observational epidemiological data 324 
suggesting that 5-ASA >1.2g/day is protective against colitis-associated cancer21. 325 
 326 
How relevant 5-ASA-mediated negative regulation of LGR5 is for established CRC remains 327 
less clear. Whilst LGR5 is commonly expressed/over-expressed in adenomas48, expression 328 
is frequently low/absent in colorectal cancers before re-expression in metastatic deposits49; 329 
indeed, LGR5+ cells appear to be important in metastatic progression58. As summarised by 330 
Morgan and colleagues59, there is abundant contradictory data on the role of LGR5 in CRC. 331 
This may be explained, at least in part, by plasticity exhibited by CSCs. Shimokawa and 332 
colleagues recently demonstrated that LGR5+ carcinoma cells differentiated into both 333 
LGR5+KRT20- and LGR5-KRT20+ daughters, and that selective ablation of LGR5 (using a 334 
CRISPR-Cas9 system) resulted initially in tumour regression followed by re-expression of 335 
LGR5 and recovery of tumour growth53. In this context, using 5-ASA to prevent the re-336 
expression of LGR5 may not only prevent tumour formation and potentially recurrence after 337 




prognosis of patients with CRC. Importantly in the 3D cultures, it was possible to 339 
demonstrate that the growth inhibitory effect of 5-ASA on the PC/AA/C1 spheroids was 340 
sustained for a further 14 days in culture after removal of the drug, suggesting that 341 
continuous administration of 5-ASA may not be necessary for either chemoprophylaxis or 342 
therapy. 343 
 344 
5-ASA is an affordable and well-tolerated drug with decades of clinical experience in the 345 
treatment of ulcerative colitis making it an outstanding candidate as a chemoprophylatic 346 
agent for patients at risk of CRC. Perhaps surprisingly for a drug that has been known for 347 
some time to suppress β-catenin activity in CRC cells, there have been a lack of clinical 348 
trials to assess the efficacy of 5-ASA in the prevention of sporadic CRC. In targeting the 349 
stemness potential of adenoma derived cells, results from this study provide new evidence 350 
to support the use of 5-ASA for the prevention of colorectal carcinogenesis. Taken together 351 
with evidence from other studies, including analysis of the effect of 5-ASA in patient 352 
samples31, we believe that robust clinical trials are now required to understand whether 353 
these findings translate into a reduction in adenoma burden in at-risk individuals. 354 
 355 
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Figure Legends 525 
Figure 1: 5-aminosalicylic acid inhibits the growth of human colonic adenoma cells as 526 
well as carcinoma cell lines in 2-dimensional culture. (A) Graphs show attached cell 527 
yield and the number of floating cells as a proportion of total cell yield of three adenoma-528 
derived cell lines (PC/AA/C1, S/AN/C1 and S/RG/C2), left, transformed adenocarcinoma 529 
cells (PC/AA/C1/SB10) and two CRC-derived cell lines (LS174T & SW620), right, 24, 48 and 530 
72 hours after treatment with 20mM and 40mM 5-ASA. Mean ± S.E.M. N=3. One-way 531 
ANOVA with Bonferroni post-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. (B) Graphs 532 
shows attached cell yield and percentage of floating cells of (i) PC/AA/C1 and (ii) S/RG/C2, 533 
after treatment with 40mM 5-ASA and 10µM Q-VD-Oph or DMSO, cells were harvested and 534 
counted at 72 hours. Mean ± S.E.M. N=3. One-way ANOVA with Bonferroni post-test, ** = p 535 
< 0.01, *** = p < 0.001.  536 
Figure 2. 5-ASA suppresses β-catenin/TCF transcriptional activity. (A-B) TOPflash 537 
reporter assay at 24 hours after 20mM and 40mM 5-ASA (A) PC/AA/C1 adenoma and (B) 538 
LS174T CRC-derived cells. Mean ± S.E.M. N=3. * = p < 0.05, ** = p < 0.01 (C) (i) Western 539 
blots of PC/AA/C1 and LS174T at 24, 48 and 72 hours after treatment with 20mM and 40mM 540 
5-ASA showing expression of active dephosphorylated and total β-catenin protein, α-tubulin 541 
used as the loading control. (ii) Densitometry graphs show the fold change of active 542 
dephosphorylated β-catenin protein as a ratio of total β-catenin expression over the 72 hour 543 
period. Expression is normalised to the respective control. Data are presented as the mean 544 
± S.E.M. of three independent experiments. N=3. One sample t-test was used to determine 545 
statistical significance. (D) Western blot of LEF-1 expression in PC/AA/C1 and LS174T cells 546 
to determine the specificity of the LEF-1 antibody. The expression level of LEF-1 was 547 
measured by western blotting 72 hour after transfection with a LEF-1 Smartpool siRNA or 548 
negative control. The results are representative of three independent experiments. Β-actin 549 
used as the loading control. (E) (i) Western blot showing PC/AA/C1 and LS174T cells after 550 




proteins AXIN-2, c-MYC and LEF-1 are all downregulated with 5-ASA with the most marked 552 
phenotype observed at 72 hours. β-actin used as the loading control. (ii) Densitometry 553 
graphs show the expression change of AXIN-2, c-MYC and LEF-1 as a fold of the loading 554 
control at the 72 hour timepoint. Expression is normalised to the respective control. Data 555 
presented as the mean ± S.E.M. of three independent experiments. N=3. One sample t-test 556 
was used to determine statistical significance. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.  557 
 558 
Figure 3. 5-ASA suppresses the expression of the stem marker LGR5. (A) Endogenous 559 
levels of LGR5 expression in a panel of colorectal adenoma and carcinoma derived cell 560 
lines. PC/AA/C1, S/AN/C1, S/RG/C2 colorectal cells, PC/AA/C1/SB10 transformed 561 
adenocarcinoma cells, HT29, HCA7, HCT116, HCT15, SW480, SW620, LOVO, LS174T 562 
colorectal adenocarcinoma cells, and SW837 and SW1463 rectal adenocarcinoma cells 563 
were grown to ~70% confluence before collection of total protein for western blot analysis. -564 
tubulin used as the loading control. (B) Western blot analysis demonstrating downregulation 565 
of LGR5 in three adenomas (PC/AA/C1, S/AN/C1 and S/RG/C2), left, transformed 566 
adenocarcinoma cells (PC/AA/C1/SB10) and two CRC-derived cell lines (LS174T and 567 
SW620), right, 24, 48 and 72 hours after treatment with 20mM and 40mM 5-ASA. β-actin 568 
used as a loading control. LGR5 is multiply glycosylated60, explaining the different banding 569 
pattern seen in the different cells.  (ii) Densitometry graphs show the expression change of 570 
LGR5 as a fold of the loading control at the 72 hour timepoint. Expression is normalised to 571 
the respective control. Data presented as the mean ± S.E.M. of three independent 572 
experiments. N=3. One sample t-test was used to determine statistical significance. * = p < 573 
0.05, ** = p < 0.01. (C) Western blots of LGR5 expression in PC/AA/C1 adenoma cells 574 
demonstrating downregulation of LGR5 after commencing treatment with 20mM and 40mM 575 
5-ASA, but subsequent reversal of this regulation once 5-ASA was withdrawn. β-actin used 576 
as a loading control. (ii) Western blot analysis of LGR5 expression in the 12 hours after 577 





Figure 4. 5-ASA reduces the ability of PC/AA/C1 adenoma and LS174T carcinoma cells 580 
to form spheroids. (A-E) PC/AA/C1 human adenoma derived cells (A) Mean number of 581 
spheroids in each well 7 days after culture. N=3 ± S.E.M. * = p < 0.05. (B) Mean log spheroid 582 
area over 21 days in culture. (C) Log spheroid area of spheroids at day 21, demonstrating 583 
distribution of spheroid size. N=1 ± S.D. representative of N=3. (D) Mean log spheroid area 584 
of spheroids at day 1. N=3 ± S.E.M. * = p < 0.05, ** = p < 0.01. (E) Representative images of 585 
PC/AA/C1-derived spheroids at day 21. Images acquired using Leica DM16000 microscope, 586 
5x lens with Leica LAS-X software. Images were processed using MatLab software. (F-I) 587 
LS174T human carcinoma derived cells (F) Mean number of spheroids in each well 7 days 588 
after culture. N=3 ± S.E.M. *** = p < 0.001 (G) Mean log spheroid area over 21 days in 589 
culture. (H) Log spheroid area of spheroids at day 21, demonstrating distribution of spheroid 590 
size. N=1 ± S.D. representative of N=3. (I) Mean log spheroid area of spheroids at day 21. 591 
N=3 ± S.E.M. ** = p < 0.01, *** = p < 0.001. (J-K) Quantitative PCR (QPCR) mRNA analysis 592 
of LGR5 and CD133 gene expression (J) PC/AA/C1- and (K) LS174T- derived spheroids 593 
after 21 days of treatment with 5-ASA. All mRNA values are normalised to the housekeeping 594 
genes TBP or HPRT. Data shows relative mRNA quantity of LGR5 and CD133 presented as 595 
a fold change of the control, which itself was normalised to one. Data are presented as the 596 
mean of three independent experiments ± S.E.M. N=3. One sample t-test was used to 597 
determine statistical significance, * = p < 0.05, ** = p < 0.01. (dRn, baseline corrected 598 
normalised fluorescence). 599 
 600 
Figure 5. The growth inhibitory effect of 5-ASA on PC/AA/C1 adenoma and LS174T 601 
carcinoma derived spheroids is sustained for 14 days after treatment is stopped. (A-D) 602 
PC/AA/C1 human adenoma derived cells (A) Mean number of spheroids per well after 7 603 
days in culture. N=3 ± S.E.M., * = p < 0.05. (B) Mean log spheroid area over 21 days in 604 




spheroid area after 21 days in culture, demonstrating distribution of spheroid size. N=1 ± 606 
S.D. (representative of N=3). (D) Mean log spheroid area of spheroids at day 21. N=3 ± 607 
S.E.M.  ** = p < 0.01 (E-H) LS174T human carcinoma derived cells (E) Mean number of 608 
spheroids per well after 7 days in culture. N=3 ± S.E.M. (F) Mean log spheroid area over 21 609 
days in culture. 5-ASA was withdrawn from the culture media on day 7. N=3 ± S.E.M. (G) 610 
Log spheroid area after 21 days in culture, demonstrating distribution of spheroid size. N=1 ± 611 
S.D. (representative of N=3). (H) Mean log spheroid area of spheroids at day 21. N=3 ± 612 
S.E.M. * = p < 0.05, ** = p < 0.01. 613 
 614 
Supplementary Figure 1 615 
(A) Graphs shows attached cell yield and percentage of floating cells of LS174T, after 616 
treatment with 40mM 5-ASA and 10µM Q-VD-Oph or DMSO, cells were harvested and 617 
counted at 72 hours. Mean ± S.E.M. N=3. One-way ANOVA with Bonferroni post-test, ** = p 618 
< 0.01, *** = p < 0.001. (ii) Western blot of cleaved PARP and cleaved Caspase 3 619 
expression in LS174T, attached and floating cells were collected and total protein was 620 
extracted at 72 hour after treatment with 40mM 5-ASA and 10µM Q-VD-Oph or DMSO, α-621 
tubulin used as the loading control. The results are representative of three independent 622 
experiments. (B) TOPflash reporter assay at 24 hours after 20mM and 40mM 5-ASA in 623 
transformed adenocarcinoma PC/AA/C1/SB10. Mean ± S.E.M. N=3. * = p < 0.05. 624 
Supplementary Figure 2 625 
(A) Western blots of S/AN/C1 and S/RG/C2 at 24, 48 and 72 hours after treatment with 626 
20mM and 40mM 5-ASA showing expression of active dephosphorylated and total β-catenin 627 
protein, α-tubulin used as the loading control. S/RG/C2 expresses a 70kDa mutant β-catenin 628 
protein, not detectable by the dephosphorylated β-catenin antibody (manuscript in 629 
preparation). (ii) Densitometry graphs show the fold change of active dephosphorylated β-630 
catenin protein as a ratio of total β-catenin expression over the 72 hour period. Expression is 631 
12 
normalised to the respective control. Data are presented as the mean ± S.E.M. of three 632 
independent experiments. N=3. One sample t-test was used to determine statistical 633 
significance. (B) Western blot showing S/AN/C1 and S/RG/C2 cells after 24, 48 and 72 634 
hours after treatment with 20mM and 40mM 5-ASA. Wnt/β-catenin target proteins AXIN-2, c-635 
MYC and LEF-1 are all downregulated with 5-ASA with the most marked phenotype 636 
observed at 72 hours. Β-actin used as the loading control. (ii) Densitometry graphs show the 637 
expression change of AXIN-2, c-MYC and LEF-1 as a fold of the loading control at the 72 638 
hour timepoint. Expression is normalised to the respective control. Data presented as the 639 
mean ± S.E.M. of three independent experiments. N=3. One sample t-test was used to 640 
determine statistical significance. * = p < 0.05, ** = p < 0.01. (C) Western blots of 641 
PC/AA/C1/SB10 and SW620 at 24, 48 and 72 hours after treatment with 20mM and 40mM 642 
5-ASA showing expression of active dephosphorylated and total β-catenin protein, α-tubulin643 
used as the loading control. (ii) Densitometry graphs show the fold change of active 644 
dephosphorylated β-catenin protein as a ratio of total β-catenin expression over the 72 hour 645 
period. Expression is normalised to the respective control. Data are presented as the mean 646 
± S.E.M. of three independent experiments. N=3. One sample t-test was used to determine 647 
statistical significance. (D) Western blot showing PC/AA/C1/SB10 and SW620 cells after 24, 648 
48 and 72 hours after treatment with 20mM and 40mM 5-ASA. Wnt/β-catenin target proteins 649 
AXIN-2, c-MYC and LEF-1 are all downregulated in PC/AA/C1/SB10 with 5-ASA with the 650 
most marked phenotype observed at 72 hours. Levels of LEF-1 are undetectable by western 651 
blotting in SW620 cells. Β-actin used as the loading control. (ii) Densitometry graphs show 652 
the expression change of AXIN-2, c-MYC and LEF-1 as a fold of the loading control at the 72 653 
hour timepoint. Expression is normalised to the respective control. Data presented as the 654 
mean ± S.E.M. of three independent experiments. N=3. One sample t-test was used to 655 
determine statistical significance. * = p < 0.05, ** = p < 0.01 656 
657 
FIG_1
FIG_2
FIG_3
FIG_4
FIG_5
FIG_S1
FIG_S2
